Related Experiment Videos
[HIV and travel].
V D'Acremont1, M L Cavassini, P E Tarr
1Centre de vaccination et de médecine des voyages Policlinique médicale universitaire de Lausanne. Valerie.Dacremont@hospvd.ch
Revue Medicale Suisse
|June 21, 2005
Summary
International travel is safer for people living with HIV (PLHIV) on antiretroviral therapy (ART). However, concerns remain regarding ART safety, drug interactions, and reduced vaccine effectiveness in PLHIV during travel.
Area of Science:
- Infectious Diseases
- Immunology
- Pharmacology
Context:
- Antiretroviral therapy (ART) has improved health for people living with HIV (PLHIV), enabling more frequent international travel.
- Travel for PLHIV presents unique challenges, including managing ART, ensuring drug adherence, and potential drug interactions.
- Increased risk and severity of travel-related infectious diseases are noted in PLHIV.
- Immunological responses to vaccines, including those for travel, can be diminished in PLHIV, even with higher CD4 counts.
Purpose:
- To highlight key considerations for PLHIV undertaking international travel.
- To address the safety and efficacy of ART and antimalarials in combination.
- To examine vaccine immunogenicity and effectiveness in PLHIV.
Summary:
- International travel is increasingly feasible for PLHIV on ART, but requires careful planning.
- Drug interactions between ART and travel medications like antimalarials are a significant concern due to limited data.
- PLHIV may experience reduced immune responses to vaccines, impacting protection against travel-related infections, with unclear clinical consequences.
Impact:
- Informs healthcare providers and PLHIV about risks and management strategies for safe international travel.
- Highlights the need for further research on drug interactions and vaccine efficacy in PLHIV.
- Aims to improve health outcomes and reduce infectious disease risks for traveling PLHIV.